Rove MagicCorner

At HHS, we reject the idea that our health system is too broken to fix. Today, @DrOzCMS and I are announcing a new Healthcare Advisory Committee—top experts from across the country coming together to provide insight on how to cut costs, reduce red tape, and put patients first. Real reform starts now.

#OCUGEN Read again and try to understand how sensational the Phase 2 data from 💉OCU410 is—seriously, not just promising, but beyond! 🤓 That's why the funds are increasing their recommendations and raising their target prices 🎯 #LETSGOOO biospace.com/press-releases…

FDA’s new guidance on Bayesian statistics is creating a lot of buzz! “The importance of the guidance cannot be overstated. It underscores FDA’s commitment to modernizing clinical research and promoting the use of bayesian methods in clinical trials.” jamanetwork.com/journals/jama/…

This is what it means. You throw the current treatments in the 🗑️🚮 Bottom line #BigPharma #GeographicAtrophy patients have a life long #OneAndDone treatment that they NEVER EVER have to go back their ophthalmologist for. It’s only routine checkups to monitor. #OCU410 $OCGN

$ocgn just showed they have the new standard of care for GA, phase 3 starts this year, market dumps early retail panics, everyone worrying about results that point to the next standard of care… Next OCU410ST Pivotal 2/3 announces enrollment completion, another blockbuster clock starts, this one comes with a PRV on approval which will be worth around $200-$250 million. OCU400 rolling BLA starts, will target 99% of the RP market and Ocugen will transform from a pre revenue bio to a leader in gene therapy’s. You can choose to focus on the day to day noise, worry about the volatility and question what you own. Or you can focus on the facts, capitalize and enjoy knowing you own the next pharmaceutical giant before the rest of the world catches on. No 🧠’er 🍻 🐂

$OCGN #OCUGEN 👇 👇 👇

Ocugen Announces Topline 12-month Data from Phase 2 ArMaDa Clinical Trial Evaluating OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration | Ocugen, Inc. share.google/ctVhjDmTKtwi12…

Ocugen Announces Topline 12-month Data from Phase 2 ArMaDa Clinical Trial Evaluating OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration | Ocugen, Inc. share.google/FhNWQSt2UGFPff…

Exciting Phase 2 results and a clear path to Phase 3 for GA.

Live Webcast Phase 2 ArMaDa trial on 3/24

$OCGN #OCUGEN 👇 👇 👇 👇 Why would you have top doctors in a field on a conference call unless it's really good data to present!!! 🤫🤫🤫

Ocugen will host a live webcast Mar 24 at 8 a.m. EDT on Phase 2 ArMaDa data for #OCU410 in GA, led by KOLs Lejla Vajzovic, MD, and Jay Chhablani, MD. Don’t miss key insights into advancements in modifier gene therapy for retinal disease. Details: bit.ly/4uJ8GgG